• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Men's Health  • Prostate Disease  • Oncology  • Prostate Cancer  • Quality of Care  • Quality of Care, Other  • Radiation Therapy  • Diagnosis  • Screening  • Less Is More  • Alert me on articles by topic  Social Bookmarking   What's this?

Comment on "Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL"

Richard M. Hoffman, MD, MPH; Steven B. Zeliadt, PhD

Arch Intern Med. 2010;170(14):1262-1263. doi:10.1001/archinternmed.2010.222

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The initial promise of PSA screening was that a simple, accurate blood test would save lives by detecting tumors at an early enough stage to be cured by aggressive treatment. Unfortunately, some 2 decades into the PSA era, the promise of early detection has been tarnished. In the United States, widespread PSA testing led to a higher incidence of early-stage disease, creating an epidemic of prostate cancer in which the lifetime risk of diagnosis increased from 9% to 16%.¹ However, a substantial proportion of these PSA-detected cancers likely never would have been found in the absence of screening.² Nevertheless, as Shao and colleagues highlight, even the lowest-risk tumors are often treated aggressively. These findings lead to the disconcerting realization that an important legacy of the PSA era might be the overdiagnosis and overtreatment of low-risk cancers. Herein, we address the potential . . . [Full Text of this Article]

AUTHOR INFORMATION
Author Affiliations: Medicine Service, New Mexico VA Health Care System, and University of New Mexico School of Medicine, Albuquerque (Dr Hoffman); Health Services Research & Development Center of Excellence, VA Puget Sound Health Care System, and Department of Health Services, University of Washington, Seattle (Dr Zeliadt).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL
Yu-Hsuan Shao, Peter C. Albertsen, Calpurnyia B. Roberts, Yong Lin, Amit R. Mehta, Mark N. Stein, Robert S. DiPaola, and Grace L. Lu-Yao
Arch Intern Med. 2010;170(14):1256-1261.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

PSA: Possible Surgery Avoidance With Use of Free PSA
Glaser
Arch Intern Med 2011;171:594-595.
FULL TEXT  

Personalized Prostate Cancer Screening: Improving PSA Tests with Genomic Information
Witte
Sci Transl Med 2010;2:62ps55-62ps55.
FULL TEXT  

Treating Prostate Cancer in Men with Low Prostate-Specific Antigen Levels
JWatch General 2010;2010:1-1.
FULL TEXT